ArticleJournal of Korean medical science2023

A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea.

Youngji Jo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.